Quinidine sulfate, which has a very similar chemical structural formula to that of quinine bisulfate, may on a rare occasion be the etiologic causative agent of an atypical secondary or symptomatic thrombocytopenic purpura of serious degree. Fortunately, the withdrawal of the drug results in a rapid return to normal of the hematologic picture. A case report of such an occurrence is presented. Three additional case reports have been collected from the literature since 1941.
A TYPICAL secondary or symptomatic thrombocytopenic purpura has been reported to develop occasionally following the ingestion of certain chemicals acting as bone marrow poisons. Some of the most com-300,000h- 3, 4, 6, 8, 9 Recently a study has been undertaken by the Department of Pharmacology and Toxicology of the University of Rochester School of Medicine and Dentistry2 to determine to what ex-438 tent therapeutic drugs and exposure to toxic chemicals may contribute to increased mortality and disability due to accidents. This study is a step in the right direction to publicize the possible deleterious effects that may follow the use of specific drugs or chemicals.
The present article represents the fourth report of purpura developing following the oral administration of quinidine sulfate to a patient with cardiac disease. Table 1 summarizes the essential data in this case as well as those of the cases reported previously.1' 5 7 An atypical secondary thrombocytopenic purpura was manifest in my patient following the use of a relatively small amount of quinidine sulfate in the treatment of auricular fibrillation. One week after recovery from the initial attack of purpura this patient was given a small test dose (0.2 Gm.) of the drug. Figure 1 graphically demonstrates the reaction. The spectacular rapid drop in the number of blood platelets in the circulating blood to 1,000 per cu. mm. one hour after the oral administration of the drug together with the fact that it required nearly twenty-four hours for the patient to recover from the severe effects of the thrombocytopenic syndrome is a grave warning that caution must be employed in the indiscriminate use of quinidine sulfate and that physicians must be on their guard when employing this valuable therapeutic agent.
Pirk and Engelbergs called attention to the fact that quinine bisulfate rather frequently may cause an atypical toxic thrombocytopenic purpura. Howard3 in his recent publication presents the chemical structural formulas of Since formulas of these two substances are quite similar, it is not surprising to find instances in which quinidine sulfate may cause a purpuric reaction similar to that caused by quinine bisulfate.
SUMMARY
The fourth reported instance of an atypical secondary severe thrombocytopenic purpura resulting from the oral ingestion of 7.2 Gm. of quinidine sulfate over a five-day period is recorded. One week following recovery a second severe atypical thrombocytopenic syndrome was produced in the patient by the oral administration of 0.2 Gm. of this drug. This brief report is made in the hope that physicians will remember that quinidine sulfate, like its more notorious "cousin," quinine bisulfate,3' 8 can cause a severe, alarming, atypical secondary thrombocytopenic purpura, which, if the etiologic factor is unrecognized, may result in the death of the patient.
